News & Comments

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed   Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric …

The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect

Important news has come from the FDA, which issued new guidelines to speed the introduction of treatments with human cells and tissues, including gene therapy. Cracking down on rogue clinics offering …

Nektar Therapeutics: Speeding Its Flight Towards the Moon

Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s fundamentals from reported finances, to reported products’ results, etc., …

 

Today’s Highlights

Could DelMar Pharmaceuticals’ Drug VAL-083 ($1 Stock Price) Defeat Glioblastoma Multiforme?

DelMar Pharmaceuticals (DMPI) -- A biopharmaceutical company focused on the development of cancer therapies provided an overview of three scientific …

Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

Yes, it is Sangamo’s (SGMO), zinc finger nuclease (ZFN) gene-editing technology, which for the first time in history enabled a patient to receive a …

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

Halozyme Therapeutics. (HALO) announced that it will present nonclinical data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer …

Cellectis allogeneic, “Off-the-Shelf” CAR T Candidate is Back in Clinical Trial

A couple of days ago, Cellectis (CLLS), which uses its own proprietary gene editing technology known as “transcription activator-like effector …

Recent Popular Posts:

Could DelMar Pharmaceuticals’ Drug VAL-083 ($1 Stock Price) Defeat Glioblastoma Multiforme?

DelMar Pharmaceuticals (DMPI) -- A biopharmaceutical company focused on the development of cancer therapies provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day of the …

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which Has Been Changed   Outstanding news announced that leukemia patients who relapsed after being treated with the chimeric receptor antigen T …

Top